EGFR and neoplasm: Recently, it has been validated that rTBL-1 retains the proapoptotic activity of its native counterpart on CRC cells in vitro (SW-480 and HT-29) in a manner linked to the recognition of tumor glycoconjugates through its carbohydrate binding pocket (CBP) [22], phosphorylation (Tyr1068), and lysosomal degradation of the EGFR, as well as phosphorylation of p38 (Thr180/Tyr182 [23]) and p53 (Ser15) [24].